论文部分内容阅读
目的探讨心脉隆注射液治疗急性失代偿性心力衰竭(ADHF)病人的疗效及安全性。方法采用随机对照研究方法,将2015年5月—2016年7月经郑州大学附属洛阳中心医院心内科治疗的ADHF病人100例,随机分为两组,心脉隆注射液治疗组和对照组。检测两组治疗前后脑钠肽(BNP)、每搏输出量(SV)、左室射血分数(LVEF)等心功能指标,观察治疗后心血管病死率、再次心衰住院率的差别。结果用药治疗1月后BNP、SV、LVEF均有明显改善(P<0.05);治疗组1月后,心血管病死率和再次住院率较对照组显著降低(P<0.05)。结论心脉隆注射液可改善心力衰竭病人心功能,改善LVEF、SV及预后。
Objective To investigate the efficacy and safety of Xinmailong Injection in the treatment of patients with acute decompensated heart failure (ADHF). Methods A randomized controlled study was conducted in 100 patients with ADHF treated by Department of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University from May 2015 to July 2016. The ADHF patients were randomly divided into two groups: Xinmailong injection group and control group. Cardiac function indexes such as brain natriuretic peptide (BNP), stroke volume (SV) and left ventricular ejection fraction (LVEF) were measured before and after treatment to observe the difference of post-treatment cardiovascular mortality and re-hospitalization rate of heart failure. Results After 1 month of treatment, the BNP, SV and LVEF were significantly improved (P <0.05). After 1 month of treatment, the cardiovascular mortality and rehospitalization rate were significantly lower than those in the control group (P <0.05). Conclusion Xinmailong injection can improve cardiac function, improve LVEF, SV and prognosis in patients with heart failure.